J. Goldman & Co’s Larimar Therapeutics LRMR Stock Holding History

J. Goldman & Co’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-18,100	Closed	-$82.4K	–	470
2023 Q4	$82.4K	Buy	+18,100	New	+$61.1K	﹤0.01%	312

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

J. Goldman & Co's LRMR Position: Q2 2026 in Review

J. Goldman & Co sold out of Larimar Therapeutics (LRMR) in Q2 2026, closing a stake of 33,756 shares — an estimated $152K sold.

J. Goldman & Co first reported a position in LRMR in Q4 2020 and held it in 12 quarters. The position peaked at $1.55M in Q4 2020. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

J. Goldman & Co reported no remaining Larimar Therapeutics position as of Q2 2026 after selling out during the quarter.
J. Goldman & Co sold 33,756 Larimar Therapeutics shares in Q2 2026, an estimated $152K.
J. Goldman & Co first reported a position in Larimar Therapeutics in Q4 2020 and held it in 12 quarters.
J. Goldman & Co's Larimar Therapeutics position peaked at $1.55M in Q4 2020.
163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.